CHANDIGARH, 09 June 2015 — Abbott, India’s leading multinational healthcare company announced the launch of ‘LiverHealth’, a new initiative aimed at providing access to an easy diagnosis of liver health and raising awareness of Hepatitis C (an infectious disease affecting the liver, caused by the Hepatitis C Virus) condition in India.
Under this initiative, for the first time in India, people in states with high prevalence of Hepatitis C infection like Punjab, Haryana, NCR region and North East will have an opportunity to have their liver health checked free of charge through a non-invasive liver imaging technology*. In a matter of a few minutes, this technology scans and determines the stage of their liver infection 1. It is also regarded as a reliable alternative for liver biopsy, an invasive technique currently used in defining the stage of liver disease 2, 3.
People at high risk of Hepatitis C are the ones undergoing medical procedures (such as blood transfusions) in a clinical setting with poor infection control practices; people who inject drugs using contaminated injection equipment; those who have used intranasal drugs or have undergone cosmetic procedures (such as tattooing, body piercing); people whose sexual partners are infected with HCV and children born to mothers infected with HCV. ***
People at high risk of Hepatitis C in the states of Punjab, Haryana and National Capital Region(NCR) can call the toll free number: 1800 209 5222 to know about the nearest place where the free liver health diagnosis is available in their city and for further information on the initiative.
Approximately 185 million people worldwide and about 12 million people in India are infected with Hepatitis C 4, 5, 6. It is estimated that the prevalence is high in the states of Punjab (5.2%) 7 and Arunachal Pradesh (7.89%) 8. Prevalence is highest among people 41–50 years of age, and men were more commonly infected than women 9. According to a WHO report, nearly 96,000 people die annually in India due to Hepatitis C, making it one of the country’s hidden epidemics 10.
Hepatitis C infection is often asymptomatic, but chronic infection** can lead to scarring of the liver and cirrhosis. Some patients may also develop liver failure, liver cancer, or life-threatening complications 11, 12, 13. Data indicates that most people (60%-80%) who have chronic hepatitis C display no symptoms and are unaware of being infected 14. Of those exposed to HCV, about 40% recover fully, but the remainder, whether they have symptoms or not, become chronic carriers. Of these, 20% develop cirrhosis. Of those with cirrhosis, up to 20% develop liver cancer 15. This clearly demonstrates the need for early diagnosis to ensure infected people can manage their disease better.
“Hepatitis C virus causes chronic infection leading to cirrhosis and may cause liver cancer. Its symptoms are not obvious and often people come for treatment at an advanced stage of liver disease,” said Dr Ajit Sood, HOD Gastroenterology, Dayanand Medical College, Ludhiana. “Hepatitis C is preventable and curable if detected and treated early. While blood tests can help determine if a person is a HCV carrier, it is critical to know the condition of the liver health to initiate treatment of Hepatitis C. Today, non-invasive techniques (like Transient Elastography) can determine the liver health accurately, enabling easy and early diagnosis of liver health which in turn will help us treat people with Hepatitis C infection better.”
“Abbott believes that good health is the starting point for achieving the most in life,” said Rehan A. Khan, Managing Director, Abbott India Limited. “We’ve been helping people in India live healthier lives for over a century and our deep understanding of the country helps us effectively identify and address unmet needs. We believe that this ‘LiverHealth’ initiative will help people seek timely diagnosis of their liver health and treatment if needed, thereby helping them live fuller lives through better health. We plan to reach out to about 1.5 lakh people in 2015 through this initiative.”
Launch of generic Sofosbuvir in India
Abbott also announced the launch of the generic version of sofosbuvir - a novel, once-daily oral treatment for people with Hepatitis C infection 16.
Sofosbuvir opens a new era in treating chronic HCV infection by increasing sustained virologic response (SVR) rates, higher cure rates, a two-to-four fold reduction in duration of treatment depending on the genotype while also minimizing treatment-related side effects 16, 17, 18, 19. Sofosbuvir should be used together with ribavirin or in combination with Peg interferon alfa and ribavirin to treat chronic hepatitis C infection 16.
Before the launch of sofosbuvir, Hepatitis C infection was treated with Pegylated interferon alfa (an antiviral drug having a dual mode of action - on viral replication and on the immune system) along with Ribavirin 20, 21. However, this therapy had challenges as far as treatment of people with liver cirrhosis due to chronic Hepatitis C infection. 20 – 60% of patients were non-responders depending on the genetic makeup of the virus# and many patients dropped from treatment due to side effects. The pharmacological properties of sofosbuvir ensure a favourable outcome as compared to other direct antiviral agents 22.
About Hepatitis C
Hepatitis C is an infectious disease affecting the liver, caused by the Hepatitis C Virus (HCV). Hepatitis C virus (HCV) is a globally prevalent pathogen and a leading cause of death and morbidity 23. It spreads primarily through blood-to-blood or body fluid contact associated with poorly sterilized medical equipment and transfusions.
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 73,000 people.
In India, Abbott has more than 14,000 employees working in manufacturing, research and development, logistics, sales and marketing and is headquartered in Mumbai.
Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.
* Transient elastography (TE) using FibroScan developed by ECHOSENS, a French diagnostic company. FibroScan is a non-invasive method for assessing liver fibrosis, with the advantages of considerable accuracy and reproducibility 24, 25. The technology is approved by USFDA and recommended by EASL, AASLD and WHO 26, 27, 28, 29
** People infected with Hepatitis C virus for more than six months
#Pegylated interferon alfa and and ribavirin fail to eradicate HCV in 50% to 60% of patients infected with genotypes 1 and 4 and in about 20% of patients infected with HCV genotypes 2 and 3 30.
2 http://www.ncbi.nlm.nih.gov/pubmed/23808910 Goyal R1, Mallick SR, Mahanta M, Kedia S, Shalimar, Dhingra R, Sharma H, Das P, Datta Gupta S, Panda S, Acharya SK.
3 Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. http://www.ncbi.nlm.nih.gov/pubmed/25682719
4 Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. HEPATOLOGY 2013;57:1333-1342.
5 Hepatitis C. World Health Organization. Available from: http://www.who.int/csr/disease/hepatitis/Hepc.pdf. Accessed on 30.04.2015
6 Dhiman RK. Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?. J Clin Exp Hepatol. 2014 Jun;4(2):85-6.
7 Sood A, Sarin SK, Midha V, et al. Prevalence of hepatitis C in a selected geographical area of northern India: a population based survey. Ind J Gastroenterol. 2012;31:132–136.
8 Phukan AC S S, Das H K, Mahanta J. HCV activity in an isolated community in north east India.; Indian J. Pathol. Microbiol. 2001; 44; 403–405
9 Saraswat V, Norris S, de Knegt RJ, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2. J Viral Hepat. 2015 Jan;22 Suppl 1:6-25.
10 Amirthalingam R, Pavalakodi VN. Prevalence of HIV-1, HCV and HBV Infections among Inhabitants in Chennai City at Hi-tech Center, Tamil Nadu-India. Medical Science, 2013, 3(8), 24-28.
11 Sharma S, Sharma A & Sharma S. Prevalence of Hepatitis C Virus in Patients of Chronic Liver Disease in Farrukhabad, (India). International Journal of Advancements in Research & Technology. 2014 October; 3(10): 69-80
12 Ryan KJ; Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed. ed.). McGraw Hill. pp. 551–2.
13 Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
14 Puri P, Anand AC, Saraswat VA, et al. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India. J Clin Exp Hepatol. 2014 Jun;4(2):106-16.
15 Hepatitis C. World Health Organization. Available from: http://www.who.int/csr/disease/hepatitis/Hepc.pdf. Accessed on 30.04.2015
16 Solvaldi (Sofosbuvir) package insert
17 Degasperi E, Aghemo A. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med. 2014 Apr 29;6:25-33.
18 Cholongitas E, Papatheodoridis GV (2014). "Sofosbuvir: a novel oral agent for chronic hepatitis C". Ann Gastroenterol 27 (4): 331–337.
19 Tran TT (December 2012). "A review of standard and newer treatment strategies in hepatitis C". Am J Manag Care 18 (14 Suppl): S340–9
20 Viral Hepatitis. European Federation of Pharmaceutical Industries and Associations (EFPIA). Available from: http://www.efpia.eu/diseases/24/59/Viral-Hepatitis. Accessed on 21.04.2015
21 Sarasin-Filipowicz M. Interferon therapy for hepatitis-C: Molecular insights into success and failure. Swiss Med Wkly. 2010;140:3-11.
22 Alberti A, Piovesan S. The evolution of the therapeutic strategy in hepatitis C: features of sofosbuvir and indications. Dig Liver Dis. 2014 Dec 15;46 Suppl 5:S174-8.
23 Cooke GS, Lemoine M, Thursz M, Gore C, Swan T, Kamarulzaman A, et al. Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat 2013;20:600-601.
24 Croagh CM, et al. Advances in the management of hepatitis C. Internal Medicine Journal 43 (2013): 1265-1271.
25 Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012 Feb;19(2):e212-9.
26 Accessed from: http://www.accessdata.fda.gov/cdrh_docs/pdf12/K123806.pdf. Accessed on 9/12/2014
27 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. Journal of Hepatology 2012 vol. 57 j 167–185
28 Who. Guidelines for the screening, care and treatment of persons with hepatitis infection, april 2014
29 http://theliverlab.com/downloads/AASLD_Endorses_FibroScan.pdf. Accessed on 14.04.2015
30 Chevaliez S, Asselah T. Mechanisms of non-response to antiviral treatment in chronic hepatitis C. Clin Res Hepatol Gastroenterol. 2011 Jun;35 Suppl 1:S31-41.